Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25


Detection rate of prostate cancer following biopsy among the northern Han Chinese population: a single-center retrospective study of 1022 cases.

Jia Y, Zhu LY, Xian YX, Sun XQ, Gao JG, Zhang XH, Hou SC, Zhang CC, Liu ZX.

World J Surg Oncol. 2017 Aug 29;15(1):165. doi: 10.1186/s12957-017-1238-9.


Use of Biomarkers in Screening for Cancer.

Duffy MJ.

EJIFCC. 2010 Mar 25;21(1):1-12. eCollection 2010 Mar.


Preparation and affinity identification of glutamic acid-urea small molecule analogs in prostate cancer.

Zhang Z, Zhu Z, Yang D, Fan W, Wang J, Li X, Chen X, Wang Q, Song X.

Oncol Lett. 2016 Aug;12(2):1001-1006. Epub 2016 Jun 10.


Active surveillance for prostate cancer.

Romero-Otero J, García-Gómez B, Duarte-Ojeda JM, Rodríguez-Antolín A, Vilaseca A, Carlsson SV, Touijer KA.

Int J Urol. 2016 Mar;23(3):211-8. doi: 10.1111/iju.13016. Epub 2015 Nov 30. Review.


Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.

Pron G.

Ont Health Technol Assess Ser. 2015 May 1;15(10):1-64. eCollection 2015. Review.


Education concerning carcinoma of prostate and its early detection.

Dutkiewcz S, Jędrzejewska S.

Cent European J Urol. 2011;64(1):15-20. doi: 10.5173/ceju.2011.01.art3. Epub 2011 Mar 18.


PSA screening for prostate cancer: why so much controversy?

Labrie F.

Asian J Androl. 2013 Sep;15(5):603-7. doi: 10.1038/aja.2013.70. Epub 2013 Jun 17.


Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion.

Basch E, Oliver TK, Vickers A, Thompson I, Kantoff P, Parnes H, Loblaw DA, Roth B, Williams J, Nam RK.

J Clin Oncol. 2012 Aug 20;30(24):3020-5. doi: 10.1200/JCO.2012.43.3441. Epub 2012 Jul 16.


Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks).

Allan GM, Chetner MP, Donnelly BJ, Hagen NA, Ross D, Ruether JD, Venner P.

Can Urol Assoc J. 2011 Dec;5(6):416-21. doi: 10.5489/cuaj.11063.


Screening for prostate cancer: early detection or overdetection?

Vickers AJ, Roobol MJ, Lilja H.

Annu Rev Med. 2012;63:161-70. doi: 10.1146/annurev-med-050710-134421. Epub 2011 Nov 3. Review.


What we have learned from randomized trials of prostate cancer screening.

Hoffman RM, Smith AY.

Asian J Androl. 2011 May;13(3):369-73. doi: 10.1038/aja.2010.181. Epub 2011 Apr 11.


Cost-effectiveness analysis of prostate cancer screening.

Hamashima C, Yoshida K.

Environ Health Prev Med. 2000 Oct;5(3):111-7. doi: 10.1265/ehpm.2000.111.


Screening for prostate cancer: a controversy or fact.

Stavridis S, Saidi S, Lekovski Lj, Dohcev S, Spasovski G.

Hippokratia. 2010 Jul;14(3):170-5.


Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials.

Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, Dahm P.

BMJ. 2010 Sep 14;341:c4543. doi: 10.1136/bmj.c4543. Review.


DNA methylation changes in prostate cancer: current developments and future clinical implementation.

Hoque MO.

Expert Rev Mol Diagn. 2009 Apr;9(3):243-57. doi: 10.1586/erm.09.10. Review.


Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies.

Ekwueme DU, Stroud LA, Chen Y.

Prev Chronic Dis. 2007 Oct;4(4):A100. Epub 2007 Sep 15. Review.


Prostate cancer pathology, screening, and epidemiology.

Crawford ED, Miller GJ, Labrie F, Hirano D, Batuello J, Glodé LM.

Rev Urol. 2001;3 Suppl 2:S2-S10.


Best practice in primary care pathology: review 4.

Smellie WS, Forth J, Sundar S, Kalu E, McNulty CA, Sherriff E, Watson ID, Croucher C, Reynolds TM, Carey PJ.

J Clin Pathol. 2006 Sep;59(9):893-902. Epub 2006 May 19. Review. Erratum in: J Clin Pathol. 2006 Oct;59(10):1116.


Current status of PSA screening. Early detection of prostate cancer.

Pickles T.

Can Fam Physician. 2004 Jan;50:57-63. Review.

Supplemental Content

Support Center